nach oben

Erschienen in:

06.04.2019 | Epidemiology

Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women

verfasst von: Serena C. Houghton, A. Heather Eliassen, Shumin M. Zhang, Jacob Selhub, Bernard A. Rosner, Walter C. Willett, Susan E. Hankinson

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We examined the association of plasma B-vitamins and metabolites, and related genetic variants, with risk of breast cancer among predominantly premenopausal women.

Methods

We conducted a nested case–control study within the Nurses’ Health Study II. From blood samples collected in 1996–1999 and follow-up through 2007, plasma measures were available for 610 cases and 1207 controls. Unconditional multivariable logistic regression was used to estimate relative risks (RR) of breast cancer and 95% confidence intervals (CIs). We examined whether associations varied by methylenetetrahydrofolate reductase (MTHFR) and dihydrofolate reductase polymorphisms, breast cancer risk factors, or tumor characteristics.

Results

Plasma vitamin B₁₂ was associated with a 64% higher risk of breast cancer comparing the highest versus lowest quintile (95% CI 1.17–2.29, p-trend = 0.02). Plasma folate (comparable RR = 1.18, 95% CI 0.84–1.66), pyridoxal 5′-phosphate (RR = 1.18, 95% CI 0.85–1.64), homocysteine (RR = 0.93, 95% CI 0.67–1.28), cysteine (RR = 1.14, 95% CI 0.81–1.62), and cysteinylglycine (RR = 0.93, 95% CI 0.66–1.31) were not associated with overall breast cancer risk. Folate was significantly positively associated with invasive and estrogen receptor-positive/progesterone receptor-positive breast cancer, and this association was suggestively stronger for bloods collected post-fortification. Several nutrient/breast cancer associations varied across subgroups defined by age, smoking, alcohol, multivitamin use, and MTHFR status (p-interaction < 0.05).

Conclusions

Overall, plasma B-vitamins and metabolites were not associated with lower breast cancer risk. Plasma vitamin B-12 was positively associated with higher risk of overall breast cancer, and plasma folate was positively associated with risk of invasive breast cancer. Additionally, there may be associations in subgroups defined by related genetic variants, breast cancer risk factors, and tumor factors. Further studies in younger women and in the post-fortification era are needed to confirm these findings.

Nur mit Berechtigung zugänglich

Scott JM, Weir DG (1998) Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk 5:223–227CrossRefPubMed

Mason JB (2003) Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr 133(Suppl 3):941S–947SCrossRefPubMed

Nazki FH, Sameer AS, Ganaie BA (2014) Folate: metabolism, genes, polymorphisms and the associated diseases. Gene 533:11–20. https://doi.org/10.1016/j.gene.2013.09.063 CrossRefPubMed

Newman AC, Maddocks ODK (2017) One-carbon metabolism in cancer. Br J Cancer 116:1499–1504. https://doi.org/10.1038/bjc.2017.118 CrossRefPubMedPubMedCentral

Xu X, Gammon MD, Wetmur JG et al (2007) A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr 85:1098–1102CrossRefPubMed

Johnson WG, Stenroos ES, Spychala JR et al (2004) New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A 124A:339–345. https://doi.org/10.1002/ajmg.a.20505 CrossRefPubMed

Farnham PJ, Means AL (1990) Sequences downstream of the transcription initiation site modulate the activity of the murine dihydrofolate reductase promoter. Mol Cell Biol 10:1390–1398CrossRefPubMedPubMedCentral

Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113. https://doi.org/10.1038/ng0595-111 CrossRefPubMed

van der Put NM, Gabreëls F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051. https://doi.org/10.1086/301825 CrossRefPubMedPubMedCentral

10.

Ericson U, Borgquist S, Ivarsson MIL et al (2010) Plasma folate concentrations are positively associated with risk of estrogen receptor beta negative breast cancer in a Swedish nested case control study. J Nutr 140:1661–1668. https://doi.org/10.3945/jn.110.124313 CrossRefPubMed

11.

Cooper AJ (1983) Biochemistry of sulfur-containing amino acids. Annu Rev Biochem 52:187–222. https://doi.org/10.1146/annurev.bi.52.070183.001155 CrossRefPubMed

12.

Brosnan JT, Brosnan ME (2006) The sulfur-containing amino acids: an overview. J Nutr 136:1636S–1640SCrossRefPubMed

13.

Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 31:273–300CrossRefPubMed

14.

Faintuch J, Aguilar PB, Nadalin W (1999) Relevance of N-acetylcysteine in clinical practice: fact, myth or consequence? Nutr Burbank Los Angel Cty Calif 15:177–179CrossRef

15.

Calaf GM, Urzua U, Termini L, Aguayo F (2018) Oxidative stress in female cancers. Oncotarget 9:23824–23842. https://doi.org/10.18632/oncotarget.25323

16.

Paolicchi A, Dominici S, Pieri L et al (2002) Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 64:1027–1035CrossRefPubMed

17.

Agnoli C, Grioni S, Krogh V et al (2016) Plasma riboflavin and vitamin B-6, but not homocysteine, folate, or vitamin B-12, are inversely associated with breast cancer risk in the european prospective investigation into cancer and nutrition-varese cohort. J Nutr 146:1227–1234. https://doi.org/10.3945/jn.115.225433 CrossRefPubMed

18.

Wu K, Helzlsouer KJ, Comstock GW et al (1999) A prospective study on folate, B12, and pyridoxal 5′-phosphate (B6) and breast cancer. Cancer Epidemiol Biomarkers Prev 8:209–217PubMed

19.

Lin J, Lee I-M, Cook NR et al (2008) Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. Am J Clin Nutr 87:734–743CrossRefPubMed

20.

Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66:2476–2482. https://doi.org/10.1158/0008-5472.CAN-05-3369 CrossRefPubMed

21.

Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res BCR 10:R67. https://doi.org/10.1186/bcr2128 CrossRefPubMed

22.

Collins LC, Marotti JD, Baer HJ, Tamimi RM (2008) Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 100:218–221. https://doi.org/10.1093/jnci/djm270 CrossRefPubMedPubMedCentral

23.

Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43–52CrossRefPubMed

24.

Shin-Buehring YS, Rasshofer R, Endres W (1981) A new enzymatic method for pyridoxal-5-phosphate determination. J Inherit Metab Dis 4:123–124. https://doi.org/10.1007/BF02263621 CrossRef

25.

Rosner B, Cook N, Portman R et al (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167:653–666. https://doi.org/10.1093/aje/kwm348 CrossRefPubMed

26.

Wang M, Spiegelman D, Kuchiba A et al (2016) Statistical methods for studying disease subtype heterogeneity. Stat Med 35:782–800. https://doi.org/10.1002/sim.6793 CrossRefPubMed

27.

Lee JE, Wei EK, Fuchs CS et al (2012) Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer risk in three large nested case-control studies. Cancer Causes Control CCC 23:537–545. https://doi.org/10.1007/s10552-012-9911-3 CrossRefPubMedPubMedCentral

28.

Kim SJ, Zuchniak A, Sohn K-J et al (2016) Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. Am J Clin Nutr 104:671–677. https://doi.org/10.3945/ajcn.116.133470 CrossRefPubMed

29.

Matejcic M, de Batlle J, Ricci C et al (2017) Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort. Int J Cancer 140:1246–1259. https://doi.org/10.1002/ijc.30536 CrossRefPubMed

30.

Houghton SC, Eliassen AH, Zhang SM et al (2019) Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the US. Int J Cancer 144:1929–1940. https://doi.org/10.1002/ijc.31934 CrossRefPubMed

31.

Cho E, Spiegelman D, Hunter DJ et al (2003) Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst 95:1079–1085CrossRefPubMed

32.

Cho E, Chen WY, Hunter DJ et al (2006) Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med 166:2253–2259. https://doi.org/10.1001/archinte.166.20.2253 CrossRefPubMed

33.

Farvid MS, Cho E, Chen WY et al (2014) Premenopausal dietary fat in relation to pre- and post-menopausal breast cancer. Breast Cancer Res Treat 145:255–265. https://doi.org/10.1007/s10549-014-2895-9 CrossRefPubMedPubMedCentral

34.

Arendt JFB, Nexo E (2012) Cobalamin Related Parameters and Disease Patterns in Patients with Increased Serum Cobalamin Levels. PLoS ONE. https://doi.org/10.1371/journal.pone.0045979 CrossRefPubMedPubMedCentral

35.

Arendt JFB, Pedersen L, Nexo E, Sørensen HT (2013) Elevated plasma vitamin B12 levels as a marker for cancer: A population-based cohort study. JNCI J Natl Cancer Inst 105:1799–1805. https://doi.org/10.1093/jnci/djt315 CrossRefPubMed

36.

Arendt JF, Sorensen HT, Horsfall LJ, Petersen I (2019) Elevated vitamin B12 levels and cancer risk in UK primary care: a THIN database cohort study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. https://doi.org/10.1158/1055-9965.EPI-17-1136 CrossRef

37.

Lin J, Manson JE, Selhub J et al (2007) Plasma cysteinylglycine levels and breast cancer risk in women. Cancer Res 67:11123–11127. https://doi.org/10.1158/0008-5472.CAN-07-3061 CrossRefPubMed

38.

Lin J, Lee I-M, Song Y et al (2010) Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res 70:2397–2405. https://doi.org/10.1158/0008-5472.CAN-09-3648 CrossRefPubMedPubMedCentral

39.

Chen P, Li C, Li X et al (2014) Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis. Br J Cancer 110:2327–2338. https://doi.org/10.1038/bjc.2014.155 CrossRefPubMedPubMedCentral

40.

Patterson RA, Lamb DJ, Leake DS (2003) Mechanisms by which cysteine can inhibit or promote the oxidation of low density lipoprotein by copper. Atherosclerosis 169:87–94CrossRefPubMed

41.

Stipanuk MH, Dominy JE, Lee J-I, Coloso RM (2006) Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. J Nutr 136:1652S–1659SCrossRefPubMed

42.

Jansen E, Beekhof P, Tamosiunas A et al (2015) Biomarkers of oxidative stress and redox status in a short-term low-dosed multivitamin and mineral supplementation study in two human age groups. Biogerontology 16:645–653. https://doi.org/10.1007/s10522-015-9568-x CrossRefPubMed

43.

Bravatà V (2015) Controversial roles of methylenetetrahydrofolate reductase polymorphisms and folate in breast cancer disease. Int J Food Sci Nutr 66:43–49. https://doi.org/10.3109/09637486.2014.959896 CrossRefPubMed

44.

Song J, Sohn KJ, Medline A et al (2000) Chemopreventive effects of dietary folate on intestinal polyps in Apc ± Msh2-/- mice. Cancer Res 60:3191–3199PubMed

45.

Song J, Medline A, Mason JB et al (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 60:5434–5440PubMed

46.

Mason JB (2011) Unraveling the complex relationship between folate and cancer risk. BioFactors Oxf Engl 37:253–260. https://doi.org/10.1002/biof.174 CrossRef

47.

Kalmbach RD, Choumenkovitch SF, Troen AM et al (2008) Circulating folic acid in plasma: relation to folic acid fortification. Am J Clin Nutr 88:763–768CrossRefPubMedPubMedCentral

Titel: Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women
verfasst von: Serena C. Houghton
A. Heather Eliassen
Shumin M. Zhang
Jacob Selhub
Bernard A. Rosner
Walter C. Willett
Susan E. Hankinson
Publikationsdatum: 06.04.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05223-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer

Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases

Propagation of functional estrogen receptor positive normal human breast cells in 3D cultures

The association between mammographic density and breast cancer risk in Western Australian Aboriginal women

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie